Abstract

 CADTH recommends that Yescarta should be reimbursed by public drug plans for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, who are eligible for autologous stem cell transplant (ASCT) if certain conditions are met.
 Yescarta should only be covered to treat adults with DLBCL or HGBL that did not respond to or relapsed within 12 months of first-line therapy and are eligible for ASCT.
 Yescarta should only be reimbursed for patients who have not yet been treated with chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health, and if the cost of Yescarta is reduced. It should be prescribed and administered by clinicians with expertise in lymphomas and CAR T-cell therapy in a hospital setting with adequate resources.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
